NYSE: NVONovo Nordisk A S Stock
$91.30+0.01 (+0.01%)
Updated Sep 22, 2023
NVO Price
$91.30
Fair Value Price
N/A
Market Cap
$416.33B
52 Week Low
$47.51
52 Week High
$100.88
P/E
41.58x
P/B
31.29x
P/S
12.55x
PEG
5.14x
Dividend Yield
1.13%
Revenue
$29.61B
Earnings
$9.82B
Gross Margin
84.4%
Operating Margin
42.27%
Profit Margin
33.4%
Debt to Equity
2.1
Operating Cash Flow
$13B
Beta
0.54
Next Earnings
Nov 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A
NVO Overview
Novo Nordisk A/S manufactures pharmaceutical products. Its Diabetes and Obesity Care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. Novo Nordisk was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Zen Score
–
Industry Average (24)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NVO scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVO ($91.30) is trading above its intrinsic value of $16.21, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVO is poor value based on its earnings relative to its share price (41.58x), compared to the US market average (14.52x)
P/E vs Market Valuation
NVO is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more NVO due diligence checks available for Premium users.
Be the first to know about important NVO news, forecast changes, insider trades & much more!
NVO News
Valuation
NVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
41.58x
Industry
12.89x
Market
14.52x
NVO is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NVO is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
NVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
31.29x
Industry
5.11x
NVO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NVO price to earnings growth (PEG)
For valuing profitable companies with growth potential
NVO is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
NVO's financial health
Profit margin
Revenue
$7.9B
Net Income
$2.8B
Profit Margin
35.8%
NVO's Earnings (EBIT) of $12.52B... subscribe to Premium to read more.
Interest Coverage Financials
NVO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$41.0B
Liabilities
$27.8B
Debt to equity
2.1
NVO's short-term liabilities ($23.03B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVO's short-term assets ($20.23B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$4.2B
Investing
-$1.4B
Financing
-$1.8B
NVO's operating cash flow ($13.20B)... subscribe to Premium to read more.
Debt Coverage Financials
NVO vs Biotech Stocks
Novo Nordisk A S Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.